Breaking News

Emergent BioSolutions Enters Viral Vector and Gene Therapy Arena

Invests $75mn in Canton site, advanced therapy CDMO drug substance manufacturing services expected to be available beginning in 2023.

By: Contract Pharma

Contract Pharma Staff

Emergent BioSolutions has unveiled plans to strengthen its contract development and manufacturing (CDMO) capabilities by expanding into viral vector and gene therapy. The company will invest $75 million in its Canton, MA facility, which is focused on the development and manufacturing of drug substance for live viral vaccines, including the company’s smallpox vaccine.   “Emergent’s expansion into advanced therapy CDMO services is based on our biologics expertise and a strong understanding of our ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters